Lataa...
PD-1/PD-L1 inhibitors
Tumors may adopt normal physiologic checkpoints for immunomodulation leading to an imbalance between tumor growth and host surveillance. Antibodies targeting the PD-1/PD-L1 checkpoint have shown dynamic and durable tumor regressions, suggesting a rebalancing of the host-tumor interaction. Nivolumab...
Tallennettuna:
| Julkaisussa: | Curr Opin Pharmacol |
|---|---|
| Päätekijät: | , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4516625/ https://ncbi.nlm.nih.gov/pubmed/26047524 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.coph.2015.05.011 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|